Indication: Ovarian Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rucaparib in combination with Nivolumab versus Placebo as Switch Maintenance Following Response to Front-Line Platinum-Based Chemotherapy in Patients with High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Patients with High-Grade Serous or Endometrioid
Sub-indication: Newly diagnosed, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Line of Therapy: Maintance therapy following response to front line plantinum-based therapy.
Principal Investigator: Mary Gordinier, M.D.Norton Cancer Institute
Sponsor: Clovis Oncology Inc.
Email for more information: GYN-NCIResearch@nortonhealthcare.org